Higher Risk of Kidney Graft Failure in the Presence of Anti‐Angiotensin II Type‐1 Receptor Antibodies

Reports have associated non‐HLA antibodies, specifically those against angiotensin II type‐1 receptor (AT1R), with antibody‐mediated kidney graft rejection. However, association of anti‐AT1R with graft failure had not been demonstrated. We tested anti‐AT1R and donor‐specific HLA antibodies (DSA) in...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	American journal of transplantation 2013-10, Vol.13 (10), p.2577-2589
Hauptverfasser:	Taniguchi, M., Rebellato, L. M., Cai, J., Hopfield, J., Briley, K. P., Haisch, C. E., Catrou, P. G., Bolin, P., Parker, K., Kendrick, W. T., Kendrick, S. A., Harland, R. C., Terasaki, P. I.
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Angiotensin II type‐1 receptor antibodies AT1R Autoantibodies - blood Autoantibodies - immunology Biological and medical sciences Biopsy Case-Control Studies DSA Enzyme-Linked Immunosorbent Assay Female Follow-Up Studies Graft Rejection - blood Graft Rejection - diagnosis Graft Rejection - immunology Graft Rejection - mortality Graft Survival HLA Antigens - immunology Humans Immunosuppression Therapy Kidney Diseases - blood Kidney Diseases - surgery Kidney Transplantation Male Medical sciences Middle Aged Multivariate analysis Nephrology. Urinary tract diseases Nephropathies. Renovascular diseases. Renal failure Prognosis Receptor, Angiotensin, Type 1 - immunology rejection Renal failure Studies Surgery (general aspects). Transplantations, organ and tissue grafts. Graft diseases Surgery of the urinary system Survival Rate Transplantation, Homologous Transplants & implants
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Reports have associated non‐HLA antibodies, specifically those against angiotensin II type‐1 receptor (AT1R), with antibody‐mediated kidney graft rejection. However, association of anti‐AT1R with graft failure had not been demonstrated. We tested anti‐AT1R and donor‐specific HLA antibodies (DSA) in pre‐ and posttransplant sera from 351 consecutive kidney recipients: 134 with biopsy‐proven rejection and/or lesions (abnormal biopsy group [ABG]) and 217 control group (CG) patients. The ABG's rate of anti‐AT1R was significantly higher than the CG's (18% vs. 6%, p
ISSN:	1600-6135 1600-6143
DOI:	10.1111/ajt.12395